The long courtship between Sanofi-Aventis SA and Genzyme Corp. may result in a nice dowry for BioMarin Pharmaceutical Inc.
Novato-based BioMarin (NASDAQ: BMRN) is involved because it makes Aldurazyme, a drug designed to treat a rare, inherited metabolic condition called MPS I. Genzyme sells the drug, with BioMarin receiving royalties of 39.5 percent to 50 percent.
No comments:
Post a Comment